Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2-phosphonylmethoxypropyl)adenine in mice

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 7, 1998, Pages 1568-1573

  Naesens, Lieve ^a   Bischofberger, Norbert ^c   Augustijns, Patrick ^b   Annaert, Pieter ^b   Van Den Mooter, Guy ^b   Arimilli, Murty N ^c   Kim, Choung U ^c   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^c GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BIS(ISOPROPYLOXYCARBONYLOXYMETHYL) ESTER; TENOFOVIR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; EPITHELIUM CELL; FEMALE; HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; INTESTINE MUCOSA; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RETROVIRUS; SUBCUTANEOUS DRUG ADMINISTRATION; VIRUS INHIBITION;

EID: 0031863214     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.7.1568     Document Type: Article

References (20)

1. Annaert, P., R. Kinget, L. Naesens, E. De Clercq, and P. Augustijns. 1997. Transport, uptake and metabolism of the bis(pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2). Pharm. Res. 14:492-496.
2. Arimilli, M. N., C. U. Kim, J. Dougherty, A. Mulato, R. Oliyai, J. P. Shaw, K. C. Cundy, and N. Bischofberger. 1997. Synthesis, in vitro biological evaluation, and oral bioavailability of 9-[2-phosphonylmethoxy)propyl]adenine (PMPA) prodrugs. Antivir. Chem. Chemother. 8:557-564.
3. Balzarini, J., A. Holy, J. Jindrich, L. Naesens, R. Snoeck, D. Schols, and E. De Clercq. 1993. Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob. Agents Chemother. 37: 332-338.
4. Barditch-Crovo, P., S. Deeks, J. Kahn, I. Redpath, A. Smith, F. Hwang, N. Hellmann, K. Cundy, J. Rooney, and P. Lietman. 1997. PMPA: safety, pharmacokinetics, and antiretroviral activity when administered as a single dose and for seven consecutive days to patients with HIV infection. Presented at the 10th International Conference on Antiviral Research.
5. Barditch-Crovo, P., J. Toole, C. W. Hendrix, K. C. Cundy, D. Ebeling, H. S. Jaffe, and P. S. Lietman. 1997. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxyl (9-[2-(bis(pivaloyloxymethyl)phosphonylmethoxyethyl]adenine) in HIV-infected patients. J. Infect. Dis. 176:406-413.
6. Bischofberger, N., L. Naesens, E. De Clercq, A. Fridland, R. V. Srinivas, B. L. Robbins, M. Arimilli, K. C. Cundy, C. Kim, S. Lacy, W. Lee, J.-P. Shaw, and R. Oliyai. 1997. Bis(POC)PMPA, an orally bioavailable prodrug of the antiretroviral agent PMPA, poster 214. Presented at the Fourth Conference on Retroviruses and Opportunistic Infections.
7. Cundy, K. C., P. Bardilch-Crovo, R. E. Walker, A. C. Collier, D. Ebeling, J. Toole, and H. S. Jaffe. 1995. Clinical pharmacokinetics of adefovir in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 39:2401-2405.
8. Cundy, K. C., J. A. Fishback, J.-P. Shaw, M. L. Lee, K. F. Soike, G. C. Visor, and W. A. Lee. 1994. Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys. Pharm. Res. 11:839-843.
9. Gilson, R. J., K. Chopra, I. Murray-Lyon, A. Newell, M. Nelson, R. S. Tedder, J. Toole, H. S. Jaffe, N. Hellmann, and I. V. D. Weller. 1996. Adefovir dipivoxyl (bis-POM PMEA) treatment for chronic hepatitis B infection: a placebo-controlled Phase I/II study, abstr. LB1. In 36th ICAAC Program Addendum. American Society for Microbiology, Washington. D.C.
10. Holme, E., J. Greter, C.-E. Jacobsen, S. Lindstedt, I. Nordin, B. Kristiansson, and U. Jodal. 1989. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet ii:469-473.
11. Mulato, A. S., P. L. Lamy, W. Li, M. D. Miller, and J. M. Cherrington. 1997. Genotypic characterization of HIV-1 variants isolated from AIDS patients after prolonged therapy with adefovir dipivoxyl (bis-POM PMEA), abstr. I-114. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
12. Naesens, L., J. Balzarini, N. Bischofberger, and E. De Clercq. 1996. Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob. Agents Chemother. 40:22-28.
13. Naesens, L., J. Balzarini, and E. De Clercq. 1992. Acyclic nucleoside phosphonates in plasma determined by high-performance liquid chromatography with fluorescence detection. Clin. Chem. 38:480-485.
14. Naesens, L., R. Snoeck, G. Andrei, J. Balzarini, J. Neyts, and E. De Clercq. 1997. HPMPC (cidofovir). PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antivir. Chem. Chemother. 8:1-23.
15. Robbins, B., R. Srinivas, C. Kim, N. Bischofberger, and A. Fridland. 1998. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob. Agents Chemother. 42:612-617.
16. Shaw, J.-P., M. S. Louie, V. V. Krishnamurthy, M. N. Arimilli, R. J. Jones, A. M. Bidgood, W. A. Lee, and K. C. Cundy. 1997. Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats. Drug Metab. Dispos. 25: 362-366.
17. Shaw, J.-P., C. M. Sueoka, R. Oliyai, W. A. Lee, M. N. Arimilli, C. U. Kim, and K. C. Cundy. 1997. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm. Res. 14:1824-1829.
18. Tsai, C.-C., K. E. Follis, T. W. Beck, A. Sabo, N. Bischofberger, and P. J. Dailey. 1997. Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. AIDS Res. Hum. Retroviruses 13:707-712.
19. Tsai, C.-C., K. E. Follis, A. Sabo, T. W. Beck, R. F. Grant, N. Bischofberger, R. E. Benveniste, and R. Black. 1995. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270:1197-1199.
20. Van Rompay, K. K. A., J. M. Cherrington, M. L. Marthas, C. J. Berardi, A. S. Mulato, A. Spinner, R. P. Tarara, D. R. Canfield, S. Telm, N. Bischofberger, and N. C. Pedersen. 1997. 9-[2-Phosphonylmethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob. Agents Chemother. 40:2586-2591.